Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
JOURNALS
Start Learning
3 Questions with Alicia Little: touchDERMATOLOGY Future Leader 2025
JOURNALS
Start Learning
BEACON study: Initial findings indicate briquilimab provides rapid and effective relief in chronic spontaneous urticaria
EADV 2025
JOURNALS
Start Learning
A look inside the EADV: A conversation with President Branka Marinović
touchFOCUS
Start Learning
Supporting healing in epidermolysis bullosa: Innovations and new directions for care
CE/CME ACCREDITED
touchIN CONVERSATION
Start Learning
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
CE/CME ACCREDITED
Dermatology 2025, traveller dermatology, AI, High-Magnification Dermoscopy, hand eczema, vitiligo and psoriasis
JOURNALS
Start Learning
The future of dermatology: 4 predictions for 2025
touchEXPERT OPINIONS
Start Learning
Navigating treatment choices in high-risk early-stage melanoma
CE/CME ACCREDITED
touchMDT
Start Learning
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
CE/CME ACCREDITED
bullous pemphigoid
JOURNALS
Start Learning
How dupilumab is set to transform bullous pemphigoid treatment
Layer of cells, human skin cells, medical illustration
JOURNALS
Start Learning
Could dupilumab help improve height in children with severe atopic dermatitis?

to view Favourites, Keep Notes and Track CME Credits

Favourites
Specific cord-blood DNA methylation patterns associated with risk of early-onset atopic dermatitis
View
Rare disease round-up: Pyoderma gangrenosum
View
A look inside the EADV: A conversation with President Branka Marinović
View
What roflumilast 0.3% foam brings to your psoriasis clinical toolkit
View
Introducing the touchDERMATOLOGY Future Leaders 2025
View
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
View
Advancing care for patients with infantile haemangiomas: Timing is key
View
Pathophysiological mechanisms and emerging concepts in the management of Type 2 dermatological diseases
View
Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
View
FDA approval of nemolizumab gives new treatment option for prurigo nodularis
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup